| Tofacitinib (CP690,550) |
JAK1, JAK2, JAK3, |
RA (appoved in US and Japan) |
III |
NCT00853385, NCT00814307
|
Pfizer |
|
|
Psoriasis |
III |
NCT01186744, NCT01241591, NCT01276639
|
|
|
|
IBD |
II |
NCT00615199, NCT00787202
|
|
|
|
Kidney Transplant Patients |
II |
NCT00106639, NCT00483756
|
|
|
|
Dry Eye |
II |
NCT00784719, NCT01135511
|
|
| CYT387 |
JAK1, JAK2 |
MF |
II |
NCT00935987 |
Cytopia |
| Baricitinib(INCB028050) |
JAK1, JAK2 |
RA |
II |
NCT00902486 |
Eli Lilly (Incyte) |
|
|
Psoriasis |
II (ongoing) |
NCT01490632 |
|
| Ruxolitinib(INCB018424) |
JAK1, JAK2 |
MF (approved in US and EU) |
III (ongoing) |
NCT00952289, NCT00934544
|
Incyte |
|
|
PV, ET |
II/III (ongoing) |
NCT01632904, NCT01243944, NCT00726232
|
|
|
|
Psoriasis |
II |
NCT00820950, NCT00778700, NCT00617994
|
|
|
|
Multiple myeloma |
II |
NCT00639002 |
|
|
|
RA |
II |
NCT00550043 |
|
|
|
CML, ALL, MS, AML |
II (ongoing) |
NCT00674479, NCT01251965
|
|
| TG101348 (SAR302503) |
JAK2, FLT3 |
MF |
III (ongoing) |
NCT01437787 |
TargeGen (Sanofi-Aventis) |
| Lestaurtinib (CEP-701) |
JAK2, FLT3, TrkA |
MF |
II |
NCT00494585 |
Cephalon |
|
|
PV, ET |
II |
NCT00586651 |
|
|
|
Prostate Cancer |
II |
NCT00081601 |
|
|
|
AML |
II |
NCT00079482 |
|
|
|
Psoriasis |
II |
NCT00236119, NCT00617994
|
|
| AZD1480 |
JAK1, JAK2 |
Solid tumor |
I (development discontinued) |
N/A |
Astra Zeneca |
|
|
MF |
II (ongoing) |
NCT00910728 |
|
| R348 |
JAK3, Syk |
Dry eye disease |
I |
NCT01733992 |
Rigel |
| VX-509 |
JAK3 |
RA |
II |
NCT01052194 |
Vertex Pharmaceuticals Incorporated |
| GLPG0634 |
JAK1, JAK2 |
RA |
II |
NCT01668641, NCT01384422
|
Galapagos NV |
| GSK2586184 |
JAK1 |
SLE |
I |
NCT01687309 |
GlaxoSmithKline (Galapagos NV) |
| AC-430 |
JAK2 |
RA |
I |
NCT01287858 |
Ambit Biosciences Corporation |
| Pacritinib (SB1518) |
JAK2 |
MF |
III (ongoing) |
NCT01773187 |
Wyeth |
| BMS-911543 |
JAK2 |
MF |
II |
NCT01236352 |
Bristol-Myers Squibb |
